vs
Side-by-side financial comparison of Laird Superfood, Inc. (LSF) and ROCKWELL MEDICAL, INC. (RMTI). Click either name above to swap in a different company.
ROCKWELL MEDICAL, INC. is the larger business by last-quarter revenue ($18.3M vs $13.3M, roughly 1.4× Laird Superfood, Inc.). ROCKWELL MEDICAL, INC. runs the higher net margin — -3.0% vs -13.2%, a 10.2% gap on every dollar of revenue. On growth, Laird Superfood, Inc. posted the faster year-over-year revenue change (15.0% vs -25.6%). Over the past eight quarters, Laird Superfood, Inc.'s revenue compounded faster (16.1% CAGR vs -10.1%).
Laird Superfood, Inc. develops, manufactures and sells a portfolio of plant-based functional superfood products, including premium coffee creamers, hydration blends, nutritional supplements, and plant-powered snacks. It serves health-conscious consumers through direct-to-consumer e-commerce platforms and offline retail partners, mainly operating in the North American market with a focus on sustainably sourced clean ingredients.
Rockwell Medical Inc. is a publicly traded pharmaceutical company based in Wixom, Michigan and founded in 1996 that focuses on development and commercialization of treatments against diseases such as end-stage renal disease (ESRD) and chronic kidney disease (CKD).
LSF vs RMTI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.3M | $18.3M |
| Net Profit | $-1.8M | $-554.0K |
| Gross Margin | 34.1% | 21.1% |
| Operating Margin | -13.5% | -2.2% |
| Net Margin | -13.2% | -3.0% |
| Revenue YoY | 15.0% | -25.6% |
| Net Profit YoY | -341.4% | 26.7% |
| EPS (diluted) | — | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.3M | $18.3M | ||
| Q3 25 | $12.9M | $15.9M | ||
| Q2 25 | $12.0M | $16.1M | ||
| Q1 25 | $11.7M | $18.9M | ||
| Q4 24 | $11.6M | $24.7M | ||
| Q3 24 | $11.8M | $28.3M | ||
| Q2 24 | $10.0M | $25.8M | ||
| Q1 24 | $9.9M | $22.7M |
| Q4 25 | $-1.8M | $-554.0K | ||
| Q3 25 | $-975.1K | $-1.8M | ||
| Q2 25 | $-362.2K | $-1.5M | ||
| Q1 25 | $-156.2K | $-1.5M | ||
| Q4 24 | $-398.4K | $-756.0K | ||
| Q3 24 | $-166.1K | $1.7M | ||
| Q2 24 | $-239.1K | $343.0K | ||
| Q1 24 | $-1.0M | $-1.7M |
| Q4 25 | 34.1% | 21.1% | ||
| Q3 25 | 36.5% | 14.3% | ||
| Q2 25 | 39.9% | 15.6% | ||
| Q1 25 | 41.9% | 16.1% | ||
| Q4 24 | 38.6% | 14.7% | ||
| Q3 24 | 43.0% | 22.0% | ||
| Q2 24 | 41.8% | 17.6% | ||
| Q1 24 | 40.0% | 13.5% |
| Q4 25 | -13.5% | -2.2% | ||
| Q3 25 | -7.7% | -9.9% | ||
| Q2 25 | -3.3% | -8.4% | ||
| Q1 25 | -1.9% | -7.2% | ||
| Q4 24 | -4.1% | -2.1% | ||
| Q3 24 | -2.3% | 6.8% | ||
| Q2 24 | -3.4% | 2.0% | ||
| Q1 24 | -11.0% | -5.8% |
| Q4 25 | -13.2% | -3.0% | ||
| Q3 25 | -7.6% | -11.0% | ||
| Q2 25 | -3.0% | -9.3% | ||
| Q1 25 | -1.3% | -8.0% | ||
| Q4 24 | -3.4% | -3.1% | ||
| Q3 24 | -1.4% | 5.9% | ||
| Q2 24 | -2.4% | 1.3% | ||
| Q1 24 | -10.3% | -7.6% |
| Q4 25 | — | $-0.01 | ||
| Q3 25 | — | $-0.05 | ||
| Q2 25 | — | $-0.05 | ||
| Q1 25 | — | $-0.04 | ||
| Q4 24 | — | $-0.02 | ||
| Q3 24 | — | $0.04 | ||
| Q2 24 | — | $0.01 | ||
| Q1 24 | — | $-0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.1M | $10.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $11.5M | $37.0M |
| Total Assets | $19.2M | $57.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.1M | $10.7M | ||
| Q3 25 | $5.1M | $13.6M | ||
| Q2 25 | $3.9M | $12.5M | ||
| Q1 25 | $7.0M | $11.4M | ||
| Q4 24 | $8.3M | $15.7M | ||
| Q3 24 | $7.9M | $12.3M | ||
| Q2 24 | $7.6M | $11.9M | ||
| Q1 24 | $7.1M | $6.6M |
| Q4 25 | $11.5M | $37.0M | ||
| Q3 25 | $12.8M | $37.0M | ||
| Q2 25 | $13.4M | $30.4M | ||
| Q1 25 | $13.3M | $31.5M | ||
| Q4 24 | $13.2M | $32.6M | ||
| Q3 24 | $13.1M | $29.1M | ||
| Q2 24 | $12.6M | $23.5M | ||
| Q1 24 | $12.7M | $20.6M |
| Q4 25 | $19.2M | $57.1M | ||
| Q3 25 | $18.9M | $57.5M | ||
| Q2 25 | $20.4M | $52.6M | ||
| Q1 25 | $21.5M | $54.0M | ||
| Q4 24 | $19.3M | $59.2M | ||
| Q3 24 | $18.8M | $57.1M | ||
| Q2 24 | $18.0M | $53.0M | ||
| Q1 24 | $17.6M | $50.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $68.4K | $2.3M |
| Free Cash FlowOCF − Capex | — | $2.2M |
| FCF MarginFCF / Revenue | — | 12.0% |
| Capex IntensityCapex / Revenue | — | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-1.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $68.4K | $2.3M | ||
| Q3 25 | $1.2M | $-1.3M | ||
| Q2 25 | $-2.8M | $1.8M | ||
| Q1 25 | $-1.3M | $-3.5M | ||
| Q4 24 | $339.2K | $865.0K | ||
| Q3 24 | $305.8K | $4.3M | ||
| Q2 24 | $642.7K | $1.4M | ||
| Q1 24 | $-422.3K | $-2.4M |
| Q4 25 | — | $2.2M | ||
| Q3 25 | — | $-1.5M | ||
| Q2 25 | — | $1.7M | ||
| Q1 25 | — | $-3.5M | ||
| Q4 24 | — | $470.0K | ||
| Q3 24 | — | $4.1M | ||
| Q2 24 | — | $1.2M | ||
| Q1 24 | — | $-2.5M |
| Q4 25 | — | 12.0% | ||
| Q3 25 | — | -9.6% | ||
| Q2 25 | — | 10.5% | ||
| Q1 25 | — | -18.8% | ||
| Q4 24 | — | 1.9% | ||
| Q3 24 | — | 14.4% | ||
| Q2 24 | — | 4.5% | ||
| Q1 24 | — | -11.1% |
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 1.4% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | 1.6% | ||
| Q3 24 | — | 0.7% | ||
| Q2 24 | — | 1.1% | ||
| Q1 24 | — | 0.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.57× | ||
| Q2 24 | — | 4.20× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LSF
| Wholesale | $7.0M | 52% |
| Coffee Tea And Hot Chocolate Products | $4.4M | 33% |
| Hydration And Beverage Enhancing Supplements | $1.6M | 12% |
| Other | $352.6K | 3% |
RMTI
| US | $15.9M | 87% |
| Non Us | $2.4M | 13% |
